Now Playing
Opinion|Videos|September 27, 2024
GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma
Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.
Advertisement
Episodes in this series
- Have you had clinical experience with GPRC5D bispecific therapies?
- If so, please share your experience
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
FDA OKs Pirtobrutinib in Frontline CLL/SLL
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
5